Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0365 | 1 | 1 |
Loa Loa (eye worm) | brahma associated protein | 0.0365 | 1 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0365 | 1 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0365 | 1 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0365 | 1 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0365 | 1 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.0365 | 1 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0365 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0365 | 1 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0365 | 1 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0365 | 1 | 1 |
Schistosoma mansoni | brg-1 associated factor | 0.0365 | 1 | 0.5 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0365 | 1 | 0.5 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0365 | 1 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0365 | 1 | 1 |
Onchocerca volvulus | 0.0365 | 1 | 0.5 | |
Trichomonas vaginalis | conserved hypothetical protein | 0.0365 | 1 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0365 | 1 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0365 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0365 | 1 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0365 | 1 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0365 | 1 | 1 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0365 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0365 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Alpha-cholesterol (functional) | = 72.2 % | Hypolipidemic activity was assessed by measuring alphacholesterol in Sprague-Dawley male rats at 50 mg/kg | ChEMBL. | 6502593 |
Alpha-cholesterol (functional) | = 81.7 % | Hypolipidemic activity was assessed by measuring alphacholesterol in Sprague-Dawley male rats at 50 mg/kg | ChEMBL. | 6502593 |
Cholesterol (functional) | < 62.5 mg 100ml-1 | Hypolipidemic activity was assessed by measuring cholesterol in Sprague-Dawley male rats at 50 mg/kg | ChEMBL. | 6502593 |
Cholesterol (functional) | < 69.4 mg 100ml-1 | Hypolipidemic activity was assessed by measuring cholesterol in Sprague-Dawley male rats at 50 mg/kg | ChEMBL. | 6502593 |
LD50 (ADMET) | < 2500 mg kg-1 | Evaluated for the dose that causes 50 % lethality in Sprague-Dawley male rats | ChEMBL. | 6502593 |
Liver weight (functional) | = 1920 g 100g-1 | Hypolipidemic activity of the compound was assessed by measuring liver weight in Sprague-Dawley male rats at 50 mg/kg | ChEMBL. | 6502593 |
Triglycerides (functional) | < 55.6 M | Hypolipidemic activity was assessed by measuring triglycerides in Sprague-Dawley male rats at 50 mg/kg | ChEMBL. | 6502593 |
Triglycerides (functional) | < 61.5 M | Hypolipidemic activity was assessed by measuring triglycerides in Sprague-Dawley male rats at 50 mg/kg | ChEMBL. | 6502593 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.